# Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia

> **NCT07232953** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia** · enrollment: 82 (actual)

## Conditions studied

- Acute Myeloid Leukaemia (AML)
- Hematopoietic Stem Cell Transplant (HSCT)

## Interventions

- **DRUG:** Fludarabine + Treosulfan

## Key facts

- **NCT ID:** NCT07232953
- **Lead sponsor:** Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-10
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07232953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07232953, "Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07232953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*